GKIM
RARE icon

GW&K Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

GW&K Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8M Buy
1,615,426
+240,019
+17% +$5.4M 0.3% 124
2025
Q4 		$31.6M Buy
1,375,407
+225,238
+20% +$7.41M 0.27% 143
2025
Q3 		$34.6M Buy
1,150,169
+668,881
+139% +$20.1M 0.31% 130
2025
Q2 		$17.5M Sell
481,288
-20,923
-4% -$754K 0.16% 215
2025
Q1 		$18.2M Sell
502,211
-7,334
-1% -$305K 0.17% 210
2024
Q4 		$21.4M Buy
509,545
+42,976
+9% +$2.13M 0.18% 199
2024
Q3 		$25.9M Buy
466,569
+60,050
+15% +$3.06M 0.22% 182
2024
Q2 		$16.7M Buy
406,519
+103,142
+34% +$4.4M 0.15% 213
2024
Q1 		$14.2M Sell
303,377
-4,152
-1% -$196K 0.12% 225
2023
Q4 		$14.7M Sell
307,529
-3,386
-1% -$131K 0.14% 210
2023
Q3 		$11.1M Buy
310,915
+24,444
+9% +$968K 0.11% 230
2023
Q2 		$13.2M Buy
286,471
+223,157
+352% +$10.4M 0.13% 211
2023
Q1 		$2.54M Buy
+63,314
New +$2.72M 0.02% 297

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

GW&K Investment Management's RARE Position: Q1 2026 in Review

GW&K Investment Management increased its Ultragenyx Pharmaceutical (RARE) stake by 17% in Q1 2026, buying an estimated $5.4M and bringing the position to 1,615,426 shares worth $33.8M. The position accounts for 0.3% of the portfolio, ranked #124.

GW&K Investment Management first reported a position in RARE in Q1 2023 and has held it in 13 quarters since. The position peaked at $34.6M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • GW&K Investment Management held 1,615,426 shares of Ultragenyx Pharmaceutical worth $33.8M as of Q1 2026.
  • GW&K Investment Management bought 240,019 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.4M.
  • Ultragenyx Pharmaceutical made up 0.3% of GW&K Investment Management's portfolio in Q1 2026, its #124 holding.
  • GW&K Investment Management first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
  • GW&K Investment Management's Ultragenyx Pharmaceutical position peaked at $34.6M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.